Akihiko Koyama

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Chad J. Swanson, Yong Zhang, Shobha Dhadda et al. · Alzheimer s Research & Therapy · 2021 · 757 citations · Full text

Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein

Masayasu Okochi, Jochen Walter, Akihiko Koyama et al. · Journal of Biological Chemistry · 2000 · 507 citations · Full text

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

Eric McDade, Jeffrey L. Cummings, Shobha Dhadda et al. · Alzheimer s Research & Therapy · 2022 · 260 citations · Full text

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease

Kanta Horie, Gemma Salvadó, Nicolas R. Barthélemy et al. · Nature Medicine · 2023 · 232 citations · Full text

Human P301L-Mutant Tau Expression in Mouse Entorhinal-Hippocampal Network Causes Tau Aggregation and Presynaptic Pathology but No Cognitive Deficits

Julie A. Harris, Akihiko Koyama, Sumihiro Maeda et al. · PLoS ONE · 2012 · 146 citations · Full text

Synaptic Transmission, Neurochemical Biomarkers, Synaptic Signaling +22